» Articles » PMID: 16417652

BRCA1 and BRCA2 Mutation Predictions Using the BOADICEA and BRCAPRO Models and Penetrance Estimation in High-risk French-Canadian Families

Overview
Specialty Oncology
Date 2006 Jan 19
PMID 16417652
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Several genetic risk models for breast and ovarian cancer have been developed, but their applicability to specific populations has not been evaluated. We used data from French-Canadian families to evaluate the mutation predictions given by the BRCAPRO and BOADICEA models. We also used this data set to estimate the age-specific risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Methods: A total of 195 families with multiple affected individuals with breast or ovarian cancer were recruited through the INHERIT (INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility) BRCAs research program. Observed BRCA1 and BRCA2 mutation status was compared with predicted carrier probabilities under the BOADICEA and BRCAPRO models. The models were assessed using Brier scores, attributes diagrams and receiver operating characteristic curves. Log relative risks for breast and ovarian cancer in mutation carriers versus population risks were estimated by maximum likelihood, using a modified segregation analysis implemented in the computer program MENDEL. Twenty-five families were eligible for inclusion in the BRCA1 penetrance analysis and 27 families were eligible for the BRCA2 penetrance analysis.

Results: The BOADICEA model predicted accurately the number of BRCA1 and BRCA2 mutations for the various groups of families, and was found to discriminate well at the individual level between carriers and noncarriers. BRCAPRO over-predicted the number of mutations in almost all groups of families, in particular the number of BRCA1 mutations. It significantly overestimated the carrier frequency for high predicted probabilities. However, it discriminated well between carriers and noncarriers. Receiver operating characteristic (ROC) curves indicate similar sensitivity and specificity for BRCAPRO and BOADICEA. The estimated risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers were consistent with previously published estimates.

Conclusion: The BOADICEA model predicts accurately the carrier probabilities in French-Canadian families and may be used for counselling in this population. None of the penetrance estimates was significantly different from previous estimates, suggesting that previous estimates may be appropriate for counselling in this population.

Citing Articles

Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Manna E, Serrano D, Cazzaniga L, Mannucci S, Zanzottera C, Fava F Genes (Basel). 2025; 16(1).

PMID: 39858629 PMC: 11764557. DOI: 10.3390/genes16010082.


Decision aids for female BRCA mutation carriers: a scoping review.

McGarrigle S, Prizeman G, Spillane C, Byrne N, Drury A, Polus M BMJ Open. 2024; 14(6):e076876.

PMID: 38871662 PMC: 11177699. DOI: 10.1136/bmjopen-2023-076876.


Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.

Moller N, Boonen D, Feldner E, Hao Q, Larsen M, Laenkholm A Sci Rep. 2023; 13(1):8536.

PMID: 37237042 PMC: 10220031. DOI: 10.1038/s41598-023-35755-8.


The current status of risk-stratified breast screening.

Clift A, Dodwell D, Lord S, Petrou S, Brady S, Collins G Br J Cancer. 2021; 126(4):533-550.

PMID: 34703006 PMC: 8854575. DOI: 10.1038/s41416-021-01550-3.


Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network.

Fan X, Wynn J, Shang N, Liu C, Fedotov A, Hallquist M JNCI Cancer Spectr. 2021; 5(4).

PMID: 34377931 PMC: 8346699. DOI: 10.1093/jncics/pkab044.


References
1.
Tonin P, Mes-Masson A, Narod S, Ghadirian P, Provencher D . Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet. 1999; 55(5):318-24. DOI: 10.1034/j.1399-0004.1999.550504.x. View

2.
Satagopan J, Offit K, Foulkes W, Robson M, Wacholder S, Eng C . The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2001; 10(5):467-73. View

3.
Hopper J, Southey M, Dite G, Jolley D, Giles G, McCredie M . Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999; 8(9):741-7. View

4.
Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M . Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet. 2005; 117(2-3):119-32. DOI: 10.1007/s00439-005-1297-9. View

5.
Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J . Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 2005; 42(7):602-3. PMC: 1736090. DOI: 10.1136/jmg.2004.024133. View